Nanobiotix is dedicated to finding new treatments for cancer based on the combined application of nanotechnologies and biotechnologies.
Nanobiotix currently develops NanoBiodrugs which are precisely targeting abnormal cells and destroying them through the controlled generation of physical or chemical reactions triggered by external activation. Nanobiodrugs are composed of two parts:
This unique mode of action explains the accuracy of the therapeutic activity and the expected excellent tolerance. Furthermore, because the activity is triggered externally, this implies a total control of the activity of the NanoBioDrugs.
So far Nanobiotix has demonstrated both in vitro and in vivo both the accuracy of the targeting and the tolerance of the NanoBiodrugs currently under development. In vitro experiments have validated the concept of cell destruction through external activation and the absolute control of this process, with the emergence of an activation time-cell destruction function. Promising large animal studies on various cancer models and different compounds are currently under way.
Nanobiotix Provides Update on Global Development of Lead Product NBTXR3
NANOBIOTIX Authorized to Commence NBTXR3 Clinical Trial in Liver Cancers
French ANSM Grants Approval for Nanobiotix’s NBTXR3 Phase II/III Registration Trial for Soft Tissue Sarcoma
NANOBIOTIX Opens First US Office in Boston, Massachusetts
Nanobiotix’s NBTXR3 NanoXray Phase I Clinical Study Results Presented at ASCO
NANOBIOTIX Announces Development Plan for CE Marking of NBTXR3
NANOBIOTIX Selects Second Product for Development, NBTX-IV
ANSM Approves Nanobiotix’s NBTXR3 Clinical Trial for Advanced Cancers
Positive Interim Results from Nanobiotix’s Nanoparticle-Based NBTXR3 Trial for STS
Nanobiotix Announces Collaboration with Key European Nanomedicine Players
PharmaEngine Inks Strategic Deal to Accelerate Nanobiotix’s NBTXR3 Clinical Program
Nanobiotix’ Lead Compound NBTXR3 for Cancer Treatment Receives Approval for First Clinical Trial
Two Major European Players in Nanomedicine Introduces Nanomed TV
Nanobiotix Announces Closing of Series-C Financing to Advance Development of NanoXray
Company Announces Exciting Preclinical Results Using Patented Nanotechnology to Fight Tumors
Professor Andre Nel
In this interview, AZoNano speaks with Professor Andre Nel about his involvement in innovative research describing the development of a 'glass bubble' nanocarrier that could help drug formulations access pancreatic cancer cells.
Jingang Li, Ph.D.
In this interview, AZoNano speaks with Jingang Li from the University of California, Berkley, who offers an introduction to the Nobel Prize-winning technology, Optical Tweezers.
Steve Kosier, Ph.D.
In this interview, we speak with SkyWater Technology about the current state of the semiconductor industry, how nanotechnology has helped to shape this sector, and their new partnership which aims to increase the accessibility of semiconductor chips for start-ups and research groups across the Unite
The MiniCapt® Pro is a remote microbial air sampler that is ideal for the pharmaceutical manufacturing industry.
NMR spectroscopy is a characterization technique that is extensively used by chemical researchers.
Inoveno’s PE-550 is a best-selling electrospinning/spraying machine that can be used for the continuous production of nanofibers.